Cue Biopharma (CUE) Price Target Increased by 2,900.00% to 122.40
Summarize this article with:
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks CUE Cue Biopharma (CUE) Price Target Increased by 2,900.00% to 122.40 April 27, 2026 — 11:21 pm EDT Written by George Maybach for Fintel-> The average one-year price target for Cue Biopharma (NasdaqCM:CUE) has been revised to $122.40 / share. This is an increase of 2,900.00% from the prior estimate of $4.08 dated April 12, 2026. The price target is an average of many targets provided by analysts. The latest targets range from a low of $121.20 to a high of $126.00 / share. The average price target represents an increase of 583.04% from the latest reported closing price of $17.92 / share. What is the Fund Sentiment? There are 50 funds or institutions reporting positions in Cue Biopharma. This is an decrease of 7 owner(s) or 12.28% in the last quarter. Average portfolio weight of all funds dedicated to CUE is 0.08%, an increase of 329.12%. Total shares owned by institutions increased in the last three months by 20.66% to 21,790K shares. The put/call ratio of CUE is 0.08, indicating a bullish outlook. What are Other Shareholders Doing? Bleichroeder holds 6,819K shares representing 209.48% ownership of the company. No change in the last quarter. Catalytic Wealth RIA holds 4,632K shares representing 142.28% ownership of the company. In its prior filing, the firm reported owning 3,432K shares , representing an increase of 25.91%. The firm decreased its portfolio allocation in CUE by 44.54% over the last quarter.
Lion Point Capital holds 2,203K shares representing 67.67% ownership of the company.
Geode Capital Management holds 803K shares representing 24.68% ownership of the company. In its prior filing, the firm reported owning 801K shares , representing an increase of 0.31%. The firm decreased its portfolio allocation in CUE by 58.76% over the last quarter.
Boothbay Fund Management holds 704K shares representing 21.64% ownership of the company. In its prior filing, the firm reported owning 611K shares , representing an increase of 13.25%. The firm decreased its portfolio allocation in CUE by 49.76% over the last quarter. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Cue Biopharma, Inc.-> Find out what the Options Markets think of Cue Biopharma, Inc.-> See our take on Cue Biopharma, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned CUE More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.